Prediction of the therapeutic response to methotrexate at 24 weeks by methotrexate–polyglutamates concentration in erythrocytes at 8 weeks in patients with rheumatoid arthritis

Modern Rheumatology

Volumn 27, Issue 3, 2017, Pages 411-416

  Murosaki, Takamasa ^a   Nagatani, Katsuya ^a   Sato, Takeo ^a   Akiyama, Yoichiro ^a   Ushijima, Kentaro ^a   Lefor, Alan Kawarai ^a   Fujimura, Akio ^a   Minota, Seiji ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Biomarker; Drug monitoring; Methotrexate; Methotrexate polyglutamates; Rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CREATININE; FOLIC ACID; GLUCOCORTICOID; METHOTREXATE; METHOTREXATE POLYGLUTAMATE; ANTIRHEUMATIC AGENT; BIOLOGICAL MARKER; POLYGLUTAMIC ACID;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DAS28; DRUG DOSE ESCALATION; DRUG EFFICACY; ERYTHROCYTE; ESTIMATED GLOMERULAR FILTRATION RATE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; GASTROINTESTINAL SYMPTOM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACODYNAMICS; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VISUAL ANALOG SCALE; ANALOGS AND DERIVATIVES; BLOOD; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOMARKERS; ERYTHROCYTES; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; POLYGLUTAMIC ACID;

EID: 84979081127     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1080/14397595.2016.1208137     Document Type: Article

References (22)

1. Rheumatoid Arthritis Clinical Trial Archive Group. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. J Rheumatol. 1995;22:218–23.
2. McKendry RJ, Dale P., Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. J Rheumatol. 1993;20:1850–6.
3. Bressolle F, Bologna C, Kinowski JM, Arcos B, Sany J, Combe B., Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol. 1997;24:1903–9.
4. Tishler M, Caspi D, Graff E, Segal R, Peretz H, Yaron M., Synovial and serum levels of methotrexate during methotrexate therapy of rheumatoid arthritis. Br J Rheumatol. 1989;28:422–3.
5. Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J., Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet. 1996;30:194–210.
6. Danila MI, Hughes LB, Brown EE, Morgan SL, Baggott JE, Arnett DK, et al. Measurement of erythrocyte methotrexate polyglutamate levels:ready for clinical use in rheumatoid arthritis? Curr Rheum Rep. 2010;12:342–7.
7. Dalrymple JM, Stamp LK, O'Donnell JL, Chapman PT, Zhang M, Barclay ML., Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis Rheum. 2008;58:3299–308.
8. de Rotte MC, den Boer E, de Jong PH, Pluijm SM, Bulatovic Calasan M, Weel AE, et al. Methotrexate polyglutamates in erythrocytes are associated with lower disease activity in patients with rheumatoid arthritis. Ann Rheum Dis. 2015;74:408–14.
9. Dervieux T, Greenstein N, Kremer J., Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. Arthritis Rheum. 2006;54:3095–103.
10. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Walsh M, et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum. 2004;50:2766–74.
11. Woolf RT, West SL, Arenas-Hernandez M, Hare N, Peters van Ton AM, Lewis CM, et al. Methotrexate polyglutamates as a marker of patient compliance and clinical response in psoriasis:a single-centre prospective study. Br J Dermatol. 2012;167:165–73.
12. Ando Y, Shimada H, Matsumoto N, Hirota T, Oribe M, Otsuka E, et al. Role of methotrexate polyglutamation and reduced folate carrier 1 (RFC1) gene polymorphisms in clinical assessment indexes. Drug Metab Pharmacokinet. 2013;28(5):442.
13. Inoue S, Hashiguchi M, Takagi K, Kawai S, Mochizuki M., Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. Yakugaku Zasshi. 2009;129:843–9.
14. Dervieux T, Orentas Lein D, Marcelletti J, Pischel K, Smith K, Walsh M, et al. HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis. Clin Chem. 2003;49:1632–41.
15. Dervieux T, Zablocki R, Kremer J., Red blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritis. Rheumatology 2010;49:2337–45.
16. Stamp LK, O'Donnell JL, Chapman PT, Zhang M, James J, Frampton C, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. Arthritis Rheum. 2010;62:359–68.
17. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham III CO, et al. Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569–81.
18. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
19. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL., Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum. 1995;38:44–8.
20. Kanda Y., Investigation of the freely available easy-to-use software ‘EZR' for medical statistics. Bone Marrow Transplant. 2013;48:452–8.
21. den Boer E, de Rotte MC, Pluijm SM, Heil SG, Hazes JM, de Jonge R., Determinants of erythrocyte methotrexate polyglutamate levels in rheumatoid arthritis. J Rheumatol. 2014;41:2167–78.
22. Dervieux T, Furst D, Lein DO, Capps R, Smith K, Caldwell J, et al. Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate:results of a multicentred cross sectional observational study. Ann Rheum Dis. 2005;64:1180–5.